Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

GSK to stop paying doctors in overhaul of sales practices

share with twitter share with LinkedIn share with facebook
12/17/2013 | 06:55am EDT
A GlaxoSmithKline logo is seen outside one of its buildings in west London, ahead of company results

LONDON (Reuters) - GlaxoSmithKline will stop paying doctors for promoting its drugs and scrap prescription targets for its marketing staff - a first for an industry battling scandals over its sales practices, and a challenge for its peers to follow suit.

Britain's biggest drugmaker also said on Tuesday it would stop payments to healthcare professionals for attending medical conferences as it tries to persuade critics it is addressing conflicts of interest that could put commercial interests ahead of the best outcome for patients.

The move may force other companies to act, since the entire drugs industry has been under fire for aggressive marketing tactics in recent years.

"Where GSK leads we must hope that other companies will follow," Fiona Godlee, editor of the British Medical Journal and an influential campaigner against undue industry influence in medical practice, told Reuters.

"But there is a long way to go if we are to truly to extricate medicine from commercial influence. Doctors and their societies have been too ready to compromise themselves."

GlaxoSmithKline's (>> GlaxoSmithKline plc) move comes amid a major bribery investigation in China, where police have accused it of funnelling up to 3 billion yuan ($494 million) to travel agencies to facilitate bribes to boost its drug sales.

However, the company said the measures were not directly related to its Chinese problems and were rather part of a broad effort to improve transparency.

In the United States, the industry's biggest market by far, many companies have run into conflicts over improper sales tactics and GSK reached a record $3-billion settlement with the U.S. government last year over charges that it provided misleading information on certain drugs.

A number of other firms have taken some steps to clean up their marketing practices and companies are being forced to disclose payments to doctors under U.S. healthcare law.

Shares in GSK, which have been hit in recent months by its woes in China and a resulting fall in sales, slid 1 percent against a 0.3 percent dip on London's blue-chip FTSE <.FTSE> index.


AstraZeneca (>> AstraZeneca plc) said in 2011 it was scrapping payments for doctors to attend international congresses but others, until now, have not followed suit and GSK's actions go further.

An AstraZeneca spokeswoman said on Tuesday it had tightened up practices in 2011 so that its actions could not be seen as an inducement for doctors to prescribe its products.

Officials at other major drug companies were not immediately available to comment.

Tim Reed, head of Health Action International, an Amsterdam-based non-government organisation critical of Big Pharma, said the GSK move would increase the pressure on other companies.

"I think other companies will follow suit - but one of the biggest problems is that the industry persists in regulating itself," he said. "The only way to properly control promotion is strong and enforced regulation by the state."

GSK's Chief Executive Andrew Witty said in a statement that his company's actions were designed to ensure that patients' interests always came first.

"We recognise that we have an important role to play in providing doctors with information about our medicines, but this must be done clearly, transparently and without any perception of conflict of interest," he said.

The decision to stop payments to doctors for speaking about medicines during meetings with other prescribers marks a big shift for a global industry that has always relied heavily on the influence of experts in promoting products.

GSK said it aimed to implement this move and a related measure to end paying for doctors to attend medical conferences by the start of 2016.

The company currently spends some 50 million pounds ($82 million) a year on paying doctors to speak or attend conferences, according to estimates from industry sources.


The change in payments to GSK's sales representatives will be implemented faster, following a successful test-run in the United States, where payments have been decoupled from the number of prescriptions generated since 2011.

The policy of ending individual sales targets will now be rolled out globally. GSK said it planned to implement the new compensation system in all countries by early 2015.

Its U.S. ?Patient First' programme bases pay for commercial staff on a mix of qualitative measures and the overall business performance, rather than the number of prescriptions generated.

Vivienne Nathanson, head of science and ethics at the British Medical Association, said this approach made sense for patient care.

"It is pleasing to see a large pharmaceutical company like GlaxoSmithKline recognise that it can reduce the possibility of undue influence by rewarding employees for providing high-quality information and education for doctors rather than for their sales figures," she said.

GSK will still pay fees to doctors carrying out company-sponsored clinical research, advisory activities and market research, which it said were essential in providing insights on specific diseases. ($1 = 6.0715 Chinese yuan) ($1 = 0.6136 British pounds)

(Additional reporting by Kate Kelland; Editing by Sophie Walker)

By Ben Hirschler

Stocks treated in this article : AstraZeneca plc, GlaxoSmithKline plc
Valeurs citées dans l'article : AstraZeneca plc, GlaxoSmithKline plc
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.43% 8562 Delayed Quote.13.21%
BEST INC. -7.36% 3.02 Delayed Quote.-45.68%
GLAXOSMITHKLINE PLC -0.99% 1472 Delayed Quote.-16.38%
HOPE, INC. 4.17% 5250 End-of-day quote.63.04%
SHIFT, INC. 2.86% 14410 End-of-day quote.80.58%
US DOLLAR / CHINESE YUAN RENMINBI (USD/CNY) -0.46% 6.773 Delayed Quote.-2.79%
share with twitter share with LinkedIn share with facebook
All news about ASTRAZENECA PLC
04:00a'WE'RE CONFIDENT' : Russia to share legal risks of COVID-19 vaccine
01:13aCOVID-19 vaccine verdicts loom as next big market risk
09/21ASTRAZENECA : Merck Get CHMP Positive Opinions for Expanded Lynparza Use
09/21ASTRAZENECA : Lynparza reduced the risk of death by 31% in BRCA1/2 or ATM-mutate..
09/21ASTRAZENECA : Lynparza recommended for approval in the EU by CHMP for BRCA-mutat..
09/21ASTRAZENECA : Lynparza recommended for approval in EU by CHMP as 1st-line mainte..
09/21Trump suggests Pfizer could win U.S. COVID-19 vaccine approval, JNJ to come l..
09/21Trump suggests Pfizer could win U.S. COVID-19 vaccine approval, JNJ to come l..
09/21EXCLUSIVE : EU in early talks with Italy's ReiThera over potential vaccine suppl..
09/21EU in early talks with Italy's ReiThera over potential vaccine supply deal -s..
More news
Financials (USD)
Sales 2020 26 681 M - -
Net income 2020 3 071 M - -
Net Debt 2020 12 916 M - -
P/E ratio 2020 51,3x
Yield 2020 2,55%
Capitalization 145 B 145 B -
EV / Sales 2020 5,91x
EV / Sales 2021 5,18x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 116,37 $
Last Close Price 110,38 $
Spread / Highest target 40,8%
Spread / Average Target 5,42%
Spread / Lowest Target -40,2%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC13.21%144 555
JOHNSON & JOHNSON-0.53%382 023
ROCHE HOLDING AG7.64%314 692
MERCK & CO., INC.-8.60%210 256
PFIZER, INC.-6.51%200 159
NOVARTIS AG-11.23%196 086